¶ÈÀÓ¾Ò²ð

2007ǯ

¸¶ÃøÏÀʸ¡¿¾ÉÎãÊó¹ð

  1. Yoshimura M, Isotani T,Irisawa S, Isotani T, Yamada K, Kikuchi M, Okugawa G, Yagyu T, Kinoshita T,Strik W,Dierks T ; A pharmaco-EEG study on antipsychotic drugs in healthy volunteers.Psychopharmacology191(4):995-1004
  2. Okugawa G, Tamagaki C, Agartz I ; Frontal and temporal volume size of grey and white matter in patients with schizophrenia An MRI parcellation study.
    Eur Arch Psychiatry Clin Neurosci 257:304-307
  3. Okugawa G, Nobuhara K, Takase K, Saito Y, Yoshimura M, Kinoshita T ; Olanzapine Increases Grey and White Matter Volumes in the Caudate Nucleus of Patients with Schizophrenia¡¥Neuropsychobiology 55:43-46
  4. Wakeno M, Okugawa G, Takeshita Y, Kato M, Fukuda T, Yamashita M, Hosoi Y, Azuma J, Kinoshita T et. al. ; Delirium Associated with Paroxetine in an Elderly Depressive Patient: A Case Report¡¥Pharmacopsychiatry 40:199-200
  5. Varnas K, Okugawa G,Hammarberg A, Nesvag R, Rimol LM, Frank J, Agratz I ; Cerebellar volumes in men with schizophrenia and alcohol dependence¡¥
    Psychiatry and Clinical Neurosciences 61:326-329
  6. Yoshida T, Ha-Kawa S, Yoshimura M, Nobuhara K, Kinoshita T, Sawada S ; Effectiveness of treatment with donepezil hydrochloride and changes in regional cerebral blood flow in patients with Alzheimer’s disease¡¥Ann Nucl Med. Jul21(5):257-265.
  7. Serretti A, Kato M, Ronchi D De and Kinoshita T ; Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients¡¥
    Molecular Psychiatry12:247-257
  8. Tamagaki C, Murata A, Ohara T, Sakata T, Takase K, Okugawa G, Nobuhara K and Kinoshita T et.al. ; Adrenoleukodystrophy initially presenting with symptoms of dementia¡¥PSYCHOGERIATRICS 7:163-165
  9. Okugawa G, Nobuhara K, Takase K, Kinoshita T ; Cerebellar Posterior Superior Vermis and Cognitive Cluster Scores in Drug-Naive Patients with First-Episode Schizophrenia¡¥Neuropsychobiology56: 216-219
  10. Kato M, Wakeno M, Okugawa G, Fukuda T, Azuma J, Kinoshita T, Serretti A ; No Association of TPH1 218A/C Polymorphism with Treatment Response and Intolerance to SSRIs in Japanese Patients with Major Depression.Neuropsychobiology56:167-171.
  11. Suzuki T, Tamura N ; System for Judgment of Depressive Tendency from Speech Analysis¡¥Electronics and Communications in Japan, Part2: 90(10) 103-114
  12. ¾åÌîÀéÊ桤¿¥ÅÄ͵¹Ô¡¢°æ¾å²íÀ²¡¢Í­Ìڱʻҡ¢²À¾ìÈþÊæ¡¢ÌÚ²¼Íøɧ ; À­ÓϹ¥°Û¾ï¤òȼ¤¦¹âµ¡Ç½¹­ÈÆÀ­È¯Ã£¾ã³²¡¥¡½À­ÈȺá¤È¹ÔÆ°²½Í޻ߤˤĤ¤¤Æ¡½.Àº¿À¿À·Ð³Ø»¨»ï109(7)637¡Ý653
  13. Ê÷´ßͳµª»Ò¡¤°ëë½ÓÌÀ¡¤µÈ¼¶©»Ë¡¤»³ÅÄ·½Â¤¡¤À¾ÅÄ·½°ìϺ¡¤¿¹ÅļÓÀ顤ã·Æ£¹¬»Ò¡¤Æþß· ÁÌÚ²¼Íøɧ¡¤ÌÚ¸¶Íµ ; ³ÔÎÓ¿·µ¤¸ù¤¬¶õ´ÖŪǾÅŰ̳èÆ°¤Ë¤â¤¿¤é¤¹±Æ¶Á¡¥
    ºÅ̲¤È²Ê³Ø22(1) 41-45
  14. ¾åÌîÀéÊ桤¿¥ÅÄ͵¹Ô¡¤°æ¾å²íÀ²¡¤Í­Ìڱʻҡ¤²À¾ìÈþÊ桤ÌÚ²¼Íøɧ ; »ùƸÀº¿À°å³Ø ¹âµ¡Ç½¹­ÈÆÀ­È¯Ã£¾ã³²¤ËÀ­ÓϹ¥°Û¾ï¤òȼ¤Ã¤¿£²¾ÉÎã¡¥³°ÍèÀº¿À°åÎÅ6(2)73¡Ý75
  15. Å«ÌÚ¹§ÌÀ¡¤±üÀî ³Ø¡¤¿¥ÅÄ͵¹Ô¡¤Ê¬ÌîÀµµ®¡¤¾åÌîÀéÊ桤¿¹ÅļÓÀ顤ÌÚ²¼Íøɧ ; ¥Ð¥ë¥×¥í»À¤¬Í¶°ø¤È¤Ê¤ê·ÚÅÙ°Õ¼±¾ã³²¤òÄ褷¤¿¤Æ¤ó¤«¤ó´µ¼Ô¤Î£±¾ÉÎã
    Âçºå¤Æ¤ó¤«¤ó¸¦µæ²ñ»¨»ï17(1)1-3
  16. ¹âÅĤ¢¤ä¡¤Ã« Ëü´î»Ò¡¤°æ¾åÇ¡¤µÈÌî¿¿µª¡¤ÎëÌÚ½ÓÌÀ¡¤¼ã»³°éϺ¡¤µÈÅĽ¡Ê¿¡¤ÌøÀ¸Î´»ë¡¤ÌÚ²¼Íøɧ ; 謁£ÎŤ¬ðôÉô¥¸¥¹¥È¥Ë¥¢´µ¼Ô¤Î¿´ÍýŪÌäÂê¤ËÍ¿¤¨¤ë±Æ¶Á¡¥
    ´ØÀ¾Íý³Ø7¡§91¡Ý96

¥Ú¡¼¥¸TOP¤ØÌá¤ë

ÁíÀ⡦²òÀâ

  1. ÌÚ²¼Íøɧ ; ºÇ¶á¤Î¤¦¤ÄɤΪ¤¨Êý¡¥³°ÍèÀº¿À°åÎÅ6(2)7-9
  2. ±ä¸¶·òÆó ; ǧÃξɤΥ±¥¢ ¥¢¥ë¥Ä¥Ï¥¤¥Þ¡¼·¿Ç§ÃξɤδÕÊÌ¿ÇÃÇ¡¥³°ÍèÀº¿À°åÎÅ6(2)86-89
  3. óîÆ£¹¬»Ò¡¤±ä¸¶·òÆ󡤱üÀî ³Ø¡¤¹âÀ¥¾¡¶µ¡¤¾åÌîÀéÊ桤ÌÚ²¼Íøɧ ; ¶¯Ç÷À­¾ã³²¤Ë¤ª¤±¤ëǾ²èÁü¸¦µæ¡¥Àº¿À²Ê¼£ÎųØ22(5)517-521
  4. ²ÃÆ£Àµ¼ù¡¤±üÀî ³Ø¡¤Ê¬ÌîÀµµ®¡¤ÖÖË̲µ±¡¤ÌÚ²¼Íøɧ ; ¥»¥í¥È¥Ë¥ó¼õÍÆÂΤª¤è¤Ó¥»¥í¥È¥Ë¥ó¥È¥é¥ó¥¹¥Ý¡¼¥¿¡¼°äÅÁ»Ò¿·¿¤¬¹³¤¦¤ÄÌô¤ÎÎ×¾²¸ú²Ì¤ËÍ¿¤¨¤ë±Æ¶Á ; Î×¾²Àº¿ÀÌôÍý10(5) 831-842
  5. ±üÀî³Ø¡¤²ÃÆ£Àµ¼ù¡¤Ê¬ÌîÀµµ®¡¤ÖÖË̲µ±¡¤¹âÀ¥¾¡¶µ¡¤µÈ¼¶©»Ë¡¤ÌÚ²¼Íøɧ ; ¥ª¡¼¥À¡¼¥á¥¤¥É°åÎŤλþÂå¤ÏÍè¤ë¤«¨¡Î×¾²ÌôÍý°äÅÁ³Ø¤Î¸½¾õ¤È²ÝÂê Î×¾²ÌôÍý°äÅÁ³Ø¤«¤é¤ß¤¿¹³¤¦¤ÄÌô¤Î¼£ÎŸú²Ìͽ¬¡¥Î×¾²Àº¿ÀÌôÍý10(8)1439-1446
  6. ÌÚ²¼Íøɧ ; ºØÆ£Àµ¸ÊÀèÀ¸ ºÇ¿·Àº¿À°å³Ø12(2) 204-205
  7. ±üÀî ³Ø ; Åý¹ç¼ºÄ´¾É¤Î¿ÇÃdzØŪ¸¦µæ¤È¼£ÎųØŪ¸¦µæ¡¥Ê¬»ÒÀº¿À°å³Ø 7(2) 68-69
  8. ÎëÌÚ͵»Ò¡¤°ÂÀƽç»Ò¡¤ÎëÌÚÊþ»Ò¡¤²¸Åľ´¡¤Æ£ÇȾ°Èþ¡¤¾®Àô¿¸°ì¡¤¹ÓÀîÊâ ; ÆüËܤˤª¤±¤ëÎ×¾²¿´Íý³Ø¤ÎƳÆþ¤È¼õÍƲáÄø£²¡Ö¿´Íý¸¦µæ¡×¤Ë¤ª¤±¤ëÀº¿ÀʬÀϳØ. ¥Ò¥å¡¼¥Þ¥ó¥µ¡¼¥Ó¥¹¥ê¥µ¡¼¥Á3:47-54
  9. ¿¥ÅÄ͵¹Ô¡¤¿ùËÜãºÈ¡¤µÈÅľ﹧ ; Q¡õA¤Ç³Ø¤ÖµßµÞ¸½¾ì¤ÎÀº¿À¾É¾õ¤»¤óÌѤξì¹ç
    EMERGENCYCARE 20(1) 73-77
  10. ¿ùËÜãºÈ¡¤¿¥ÅÄ͵¹Ô¡¤µÈÅľ﹧ ; Q¡õA¤Ç³Ø¤ÖµßµÞ¸½¾ì¤ÎÀº¿À¾É¾õ ¼«»¦´ë¿Þ¤Î¾ì¹ç­¡¡¥EMERGENCYCARE 20(2) 88-91
  11. ¿ùËÜãºÈ¡¤¿¥ÅÄ͵¹Ô¡¤µÈÅľ﹧ ; Q¡õA¤Ç³Ø¤ÖµßµÞ¸½¾ì¤ÎÀº¿À¾É¾õ ¼«»¦´ë¿Þ¤Î¾ì¹ç­¢¡¥EMERGENCYCARE 20(3) 12-15
  12. µÈÅľ﹧¡¤¿¥ÅÄ͵¹Ô¡¤¿ùËÜãºÈ ; Q¡õA¤Ç³Ø¤ÖµßµÞ¸½¾ì¤ÎÀº¿À¾É¾õ É԰¾ɾõ(²á´¹µ¤È¯ºî¤ä¥Ñ¥Ë¥Ã¥¯¾É¾õ¤Ê¤É)¤Î¾ì¹ç¡¥EMERGENCYCARE 20(4) 71-75
  13. ¿¥ÅÄ͵¹Ô¡¤µÈÅľ﹧¡¤¿ùËÜãºÈ ; Q¡õA¤Ç³Ø¤ÖµßµÞ¸½¾ì¤ÎÀº¿À¾É¾õ ¥¢¥ë¥³¡¼¥ëÍðÍÑ(ʪ¼ÁÍðÍÑ)¤Ë´ØÏ¢¤·¤¿Àº¿À¾É¾õ¤Î¾ì¹ç¡¥EMERGENCYCARE 20(5) 61-64
  14. µÈÅľ﹧¡¤¿¥ÅÄ͵¹Ô¡¤¿ùËÜãºÈ ; Q¡õA¤Ç³Ø¤ÖµßµÞ¸½¾ì¤ÎÀº¿À¾É¾õ ¿´Åª¥È¥é¥¦¥Þ¤Î¾ì¹ç(ÁÓ¼ºÂθ³¡¦Èáòȿ±þ¤Ê¤É)¡¥EMERGENCYCARE 20(6) 78-82
  15. ¿¥ÅÄ͵¹Ô¡¤µÈÅľ﹧¡¤¿ùËÜãºÈ ; Q¡õA¤Ç³Ø¤ÖµßµÞ¸½¾ì¤ÎÀº¿À¾É¾õ “¤³¤ó¤á¤¤”¤Î¾ì¹ç¡¥
    EMERGENCYCARE 20(7) 73-76
  16. ¿ùËÜãºÈ¡¤¿¥ÅÄ͵¹Ô¡¤µÈÅľ﹧ ; Q¡õA¤Ç³Ø¤ÖµßµÞ¸½¾ì¤ÎÀº¿À¾É¾õ ÉÔ̲¤Î¾ì¹ç¡¥
    EMERGENCYCARE 20(8) 81-84
  17. µÈÅľ﹧¡¤¿¥ÅÄ͵¹Ô¡¤¿ùËÜãºÈ ; Q¡õA¤Ç³Ø¤ÖµßµÞ¸½¾ì¤ÎÀº¿À¾É¾õ ǧÃξɤξì¹ç¡¥
    ENERGENCYCARE 20(9) 79-84
  18. ¿ùËÜãºÈ¡¤¿¥ÅÄ͵¹Ô¡¤µÈÅľ﹧ ; Q ¡õA¤Ç³Ø¤ÖµßµÞ¸½¾ì¤ÎÀº¿À¾É¾õ ÍÞ¤¦¤Ä¤Î¾ì¹ç¡¥
    EMERGENCYCARE 20(10) 70-73
  19. µÈÅľ﹧¡¤¿¥ÅÄ͵¹Ô¡¤¿ùËÜãºÈ ; Q¡õA¤Ç³Ø¤ÖµßµÞ¸½¾ì¤ÎÀº¿À¾É¾õ¡Ö˽¤ì¤ë¿Í¡×¤Î¾ì¹ç¡¥
    EMERGENCYCARE 20(11) 99-102
  20. ¿¥ÅÄ͵¹Ô¡¤µÈÅľ﹧¡¤¿ùËÜãºÈ ; Q¡õA¤Ç³Ø¤ÖµßµÞ¸½¾ì¤ÎÀº¿À¾É¾õ Àº¿À¾É¾õ¤òȼ¤¦´µ¼Ô¤µ¤ó¤Îž²Ê¡¦Å¾±¡¤Î¾ì¹ç¡¥EMERGENCYCARE 20(12) 67-71
  21. ¾åÌîÀéÊæ ; Àº¿À°å³ØÆþÌç Q¡õA½¸Àº¿À°å³ØÆþÌç¡¥¤³¤³¤í¤Î¤ê¤ó¤·¤ç¤¦a¡¦la¡¦carte 26(2)186-187
  22. ÎëÌÚÊþ»Ò ; ¡ÖÀº¿ÀÎÅË¡¤È¿´ÍýÎÅË¡¡×Q¡õA½¸ Àº¿ÀÎÅË¡¤È¿´ÍýÎÅË¡ Àº¿ÀÎÅË¡¤â¿´ÍýÎÅË¡¤â±Ñ¸ì¤Ç¤Ï¤É¤Á¤é¤â¥µ¥¤¥³¥»¥é¥Ô¡¼¤È¤Ê¤ê¤Þ¤¹¤¬¡¢¤½¤Î°ã¤¤¤Ï²¿¤Ç¤¹¤«¡©¡¥
    ¤³¤³¤í¤Î¤ê¤ó¤·¤ç¤¦a¡¦la¡¦carte 7:343
  23. ÎëÌÚÊþ»Ò ; ¡ÖÀº¿ÀÎÅË¡¤È¿´ÍýÎÅË¡¡×Q¡õA½¸ Àº¿ÀÎÅË¡¤È¿´ÍýÎÅË¡ Àº¿ÀÎÅË¡¤Îµ¯¸»¤Ï²¿¤Ç¤¹¤«¡©¤³¤³¤í¤Î¤ê¤ó¤·¤ç¤¦a¡¦la¡¦carte 9:344-345
  24. ÎëÌÚÊþ»Ò ; ¡ÖÀº¿ÀÎÅË¡¤È¿´ÍýÎÅË¡¡×Q¡õA½¸ Àº¿ÀÎÅË¡¤È¿´ÍýÎÅË¡ Êƹñ¤Ç¤ÏÀº¿ÀʬÀϤ¬Í­Ì¾¿Í¤Î¥¹¥Æ¥¤¥¿¥¹¤Î¤è¤¦¤Ëή¹Ô¤·¤Þ¤·¤¿¤¬¡¢¤Ê¤¼ÆüËܤǤϤ½¤¦¤Ê¤é¤Ê¤«¤Ã¤¿¤Î¤Ç¤·¤ç¤¦¤«¡©¡¥¤³¤³¤í¤Î¤ê¤ó¤·¤ç¤¦a¡¦la¡¦carte 9:364-365

¥Ú¡¼¥¸TOP¤ØÌá¤ë

2006ǯ

¸¶ÃøÏÀʸ¡¿¾ÉÎãÊó¹ð

  1. Nobuhara K, Okugawa G, Sugimoto T, Minami T, Tamagaki C, Takase K, Saito Y, Sawada S, Kinoshita T ; Frontal white matter anisotropy and symptom severity of late-life depression: a magnetic resonance diffusion tensor imaging study.J Neurol Neurosurg Psychiatry77(1)120-122.
  2. Okugawa G, Nobuhara K, Minami M, Takase K, Sugimoto T, Saito Y, Yoshimura M, Kinoshita T ; Neural disorganization in the superior cerebellar peduncle and cognitive abnormality in patients with schizophrenia: A diffusion tensor imaging study Progress in Neuro-Psychopharmacology & Biological Psychiatry 30:1408-1412
  3. Irisawa S, Isotani T, Yagyu T, Morita S, Nishida K, Sugimoto T, Saito Y, Yoshimura M, Okugawa G, Nobuhara K, Kinoshita T ; Increased Omega Complexity and Dereased Microstate Duration in Nonmedicated Schizoprenic Patients.Neuropsychobiology54:134-139
  4. Serretti A, Kato M, De Ronchi D, Kinoshita T ; Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selectiveserotonin reuptake inhibitor efficacy in depressed patients.Mol Psychiatry12(3)247-257
  5. Ha-Kawa SK, Yoshida T, Yague T,Tani M, Suzuki T, Sawada S ; Acupunctur-induced cerebral blood fiow responses in dystonia. An Nuc Med 20(1) 83-87
  6. Kato M, Fukuda T, Wakeno M, Fukuda K, Okugawa G, Ikenaga Y, Yamashita M, Takekita Y, Nobuhara K, Azuma J, Kinoshita T ; Effects of the serotonin type 2A, 3A and 3B receptor and the serotonin transporter genes on paroxetine and fluvoxamine efficacy and adverse drug reactions indepressed Japanese patients.Neuropsychobiology53(4):186-95
  7. ÌÚ²¼Íøɧ, ¹©Æ£µÁͺ, »°±ºÄ秡¤ÀîË̹¬ÃË¡¤ºæ½ÓÌÀ¡¤ã·Æ£Àµ¸Ê¾ ; Åý¹ç¼ºÄ´¾É¤ËÂФ¹¤ëaripiprazole¤Î½é´üÎ×¾²ÂèIIÁê»î¸³ ´ØÀ¾Ã϶è¿»ÜÀ߶¦Æ±¥ª¡¼¥×¥ó»î¸³.Î×¾²Àº¿ÀÌôÍý9(1)¡§95-112
  8. ¿¥ÅÄ͵¹Ô¡¤¼éÅÄÌ­¡¤ËÙÆâËãÈþ¡¤»³ÅÄ·½Â¤¡¤µÈÌî¿¿µª¡¤ÃæÊ¿¶Ç»Ò¡¤ÎëÌÚÊþ»Ò¡¤ÎëÌÚÈþº´¡¤»³ÅÄÈÞº»»Ò¡¤ÌÚ²¼Íøɧ ; FTM¤Ë¤ª¤±¤ëMMPI¤È¥Æ¥¹¥È¥¹¥Æ¥í¥óÃͤËÂФ¹¤ë¸¡Æ¤.ÆüËÜÀ­²Ê³Ø²ñ»¨»ï24(£±)¡§17-22
  9. ÅĶᰡÍö¡¤ÌøÀ¸Î´»ë¡¤¿¥ÅÄ͵¹Ô¡¤ÌÚ²¼Íøɧ¡¤À¾»³ÍøÀµ ; ½¤Àµ·¿ECT¤Ë¤è¤ë¤¦¤ÄÉ´µ¼Ô¤Î½èÊýÆâÍƤÎÊѲ½¤Ë¤Ä¤¤¤Æ.ºÇ¿·Àº¿À°å³Ø11(2):173-179
  10. ÎëÌÚÊþ»Ò¡¤ÅļľÎÉ ; ɽ¸½¤ÈǧÃΤÎÁê°ã¤«¤é¸¡Æ¤¤·¤¿´¶¾ð²»À¼¤ÎÆÃħ.¿´Íý³Ø¸¦µæ77(2):149-156
  11. °Âóî½ç»Ò¡¤ÎëÌÚÊþ»Ò¡¤ÃæëÍÛÆó ; ÂèÆó¼¡À¤³¦ÂçÀï¸å¤ÎÆüËÜÎ×¾²¿´Íý³Ø¤Î˨²ê¡ÝÎëÌÚÀ¶¤òÃæ¿´¤Ë¡Ý¡¥¿´Íý³Ø»Ë¡¦¿´Íý³ØÏÀ7/8¹çÊ»¹æ:25-37
  12. À¾ÅÄ·½°ìϺ¡¤°ëë½ÓÌÀ¡¤Æþß· Á »³ÅÄ·½Â¤¡¤ ¿¹ÅļÓÀ顤ÌÚ²¼Íøɧ¡¤µÈ¼¶©»Ë¡¤µÆÃν¼, Koenig T ; ÆüËÜÌôʪǾÇȳزñ»¨»ï8(1)36-38

¥Ú¡¼¥¸TOP¤ØÌá¤ë

ÁíÀ⡦²òÀâ

  1. ÌÚ²¼Íøɧ ; Âç³Ø¡¦Àº¿À²Ê¾Ò²ð ´ØÀ¾°å²ÊÂç³ØÀº¿À¿À·Ð²Ê¡¥ºÇ¿·Àº¿À°å³Ø11(3)¡§279-286
  2. ÌÚ²¼Íøɧ ; ÌôʪǾÇȳؤÎȯŸ¤È¤½¤Î°ÕµÁ¡¥Î×¾²¿À·ÐÀ¸Íý³Ø34(5)¡§289
  3. ±ä¸¶·òÆó ; ¡ÚÈóÄê·¿¹³Àº¿ÀÉÂÌô¤ÎÂ絬ÌÏÎ×¾²»î¸³¡Û Åý¹ç¼ºÄ´¾É¤Î¥Õ¥¡¡¼¥¹¥È¥é¥¤¥ó¼£ÎŤˤª¤±¤ëÈñÍÑÂиú²Ì»î¸³¡¥Schizophrenia Frontier7(2):111-115
  4. ¹âÀ¥¾¡¶µ, ±üÀî³Ø, µÈ¼¶©»Ë, ʬÌîÀµµ®, óîÆ£¹¬»Ò, ÌÚ²¼Íøɧ ; ¥Ù¥ó¥¾¥¸¥¢¥¼¥Ô¥ó¤¬Ç§ÃΡ¦±¿Æ°µ¡Ç½¤ËµÚ¤Ü¤¹±Æ¶Á¡¥Î×¾²Àº¿À°å³Ø35(12)¡§1653-1658
  5. ²¬Â¼¹¨Èþ ; ½¡¶µ¤È¼«Á³´Ñ¡¢½¡¶µ¿´Íý³Ø³µÏÀ(¥³¥é¥à) ¥Ê¥«¥Ë¥·¥ä½ÐÈÇ

¥Ú¡¼¥¸TOP¤ØÌá¤ë